Overall The mission of the Center for AIDS Research (CFAR) at Emory University is to decrease HIV incidence, improve well-being and, ultimately, find a vaccine and a cure for HIV by fostering and supporting trans- disciplinary research targeting the Southern epidemic as a microcosm of the global HIV/AIDS pandemic. The Emory CFAR has been extremely successful in strategically expanding a University-wide, multidisciplinary community of scientists whose NIH-funded research has led to globally recognized interventions that prevent new HIV transmissions and enhance the wellbeing of people living with and at risk for HIV. Over its 18-year history, the Emory CFAR has become the cornerstone of Emory's HIV research community and has brought the University to world prominence as a center of excellence in HIV/AIDS research. During the current project period the Emory CFAR Executive Leadership maintained a focus on immunology and pathogenesis while also greatly expanding the CFAR's capacity to provide innovative and comprehensive clinical, prevention science, and biostatistical support to HIV researchers. We have also strengthened our ties with the community through substantive partnerships with community-based, state, and national public health agencies that are focusing attention on the Southern HIV epidemic. The CFAR's success in providing Value Added to Emory University is widely acknowledged by the University leadership that has committed $3M in institutional support for the CFAR from the offices of the Emory University President, Provost, and all five units of the Woodruff Health Science Center (Emory School of Medicine, Rollins School of Public Health, Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute, and Yerkes National Primate Research Center). In addition, the Georgia Research Alliance, an external partner that promotes the growth of research in Georgia, continues their commitment to support the CFAR through the purchase of research equipment and funds for laboratory infrastructure needs. As a means of fulfilling the mission of the CFAR we propose specifically to 1) Develop, support, and expand high priority HIV/AIDS research that will prevent new infections, improve the well-being of people with or at risk for HIV, and move toward the discovery of a vaccine and a cure; 2) Translate and disseminate HIV/AIDS research findings; 3) Identify, train, mentor, and support the next generation of HIV/AIDS researchers and scientific leaders. In this way we are confident that the Emory CFAR will continue to build on its successes to develop a comprehensive research program that makes significant contributions to ending the HIV epidemic. This application is for a Center for AIDS Research award.

Public Health Relevance

In the 21st century the mitigation of suffering from HIV/AIDS remains a global challenge. The mission of the Center for AIDS Research (CFAR) at Emory University is to decrease HIV incidence, improve well-being and, ultimately, find a vaccine and a cure for HIV by fostering and supporting trans-disciplinary research targeting the Southern US epidemic as a microcosm of the global HIV/AIDS pandemic. This project will foster career development of young HIV investigators and provide innovative and comprehensive HIV research support services for new and established researchers through five science cores ? Clinical Research, Prevention Science, Biostatistics & Bioinformatics, Immunology, and Virology & Molecular Biomarkers ? and two scientific working groups: HIV & Aging and HIV Cure.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI050409-21
Application #
9752479
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Beaubien, Candice M
Project Start
2002-09-30
Project End
2022-07-31
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
21
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Emory University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Huang, Yijian; Wang, Ching-Yun (2018) Cox regression with dependent error in covariates. Biometrics 74:118-126
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Goodreau, Steven M; Hamilton, Deven T; Jenness, Samuel M et al. (2018) Targeting Human Immunodeficiency Virus Pre-Exposure Prophylaxis to Adolescent Sexual Minority Males in Higher Prevalence Areas of the United States: A Modeling Study. J Adolesc Health 62:311-319
Sullivan, Patrick S; Purcell, David W; Grey, Jeremy A et al. (2018) Patterns of Racial/Ethnic Disparities and Prevalence in HIV and Syphilis Diagnoses Among Men Who Have Sex With Men, 2016: A Novel Data Visualization. Am J Public Health 108:S266-S273
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
Luo, Wei; Katz, David A; Hamilton, Deven T et al. (2018) Development of an Agent-Based Model to Investigate the Impact of HIV Self-Testing Programs on Men Who Have Sex With Men in Atlanta and Seattle. JMIR Public Health Surveill 4:e58
Wells, Jessica S; Holstad, Marcia M; Watkins Bruner, Deborah (2018) Sociodemographic Predictors of Anal Cancer Screening and Follow-up in Human Immunodeficiency Virus-Infected Individuals. Cancer Nurs 41:424-430
Eaton, Lisa A; Kalichman, Seth C; Kalichman, Moira O et al. (2018) Randomised controlled trial of a sexual risk reduction intervention for STI prevention among men who have sex with men in the USA. Sex Transm Infect 94:40-45
Wall, Kristin M; Inambao, Mubiana; Kilembe, William et al. (2018) HIV testing and counselling couples together for affordable HIV prevention in Africa. Int J Epidemiol :
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912

Showing the most recent 10 out of 1005 publications